Prophylaxis News and Research

RSS

Belgian research project examines use of preventive HIV medication among gay men

The Institute of Tropical Medicine in Antwerp (ITM), with support from the Agency for Innovation by Science and Technology (IWT), launches the Be-PrEP-ared project on Thursday 10 September.

10 Sep 2015

HIV prevention program undergoes “real world” evaluation

A programme that provides pre-exposure prophylaxis (PrEP) to prevent HIV infection among sexually active gay men has not seen one case of HIV infection since it began in 2012, according to the first “real world” evaluation of the regimen at Kaiser Permanente San Francisco Medical Center.

4 Sep 2015

Common drug used for treating fungal infections in lung transplant recipients increases risk for skin cancer, death

Voriconazole, a prescription drug commonly used to treat fungal infections in lung transplant recipients, significantly increases the risk for skin cancer and even death, according to a new study by UC San Francisco researchers.

3 Sep 2015

European cardiomyopathies registry shows higher than expected use of defibrillators, genetic testing

The most representative snapshot of real world practice in cardiomyopathies in Europe has shown a higher than expected use of defibrillators and genetic testing. The baseline results of the ESC's EORP Cardiomyopathy Registry Pilot are presented for the first time today at ESC Congress 2015.

2 Sep 2015

New ESC Guidelines on infective endocarditis support role of imaging in diagnosis

ESC Guidelines published today on infective endocarditis boost the role of imaging in diagnosis of this deadly disease.

29 Aug 2015

Antiviral-based therapies have potential to protect humans from deadly Ebola virus

For the first time, UK physicians have demonstrated that antiviral-based therapies have the potential to protect humans from the deadly Ebola virus. The report, published in The Lancet Infectious Diseases journal, describes a case-series of eight British health-care workers who were evacuated to the Royal Free Hospital in London, UK after possible accidental exposure to Ebola virus in Sierra Leone between January and March 2015.

26 Aug 2015

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

CSL Behring announced today that the first patient has been enrolled in its Phase II/III clinical study evaluating the pharmacokinetics (PK), efficacy, and safety of the company's recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) for on-demand treatment in patients with congenital hemophilia A or B who have developed an inhibitor to factor VIII or factor IX replacement therapy.

26 Aug 2015

60P to commence Phase II clinical trial among dengue fever patients

60 Degrees Pharmaceuticals, a company focused on development of therapeutics for tropical diseases, and Singapore General Hospital announced today that the Hospital has received a grant from Singapore's National Medical Research Council to support a Phase II clinical trial among dengue fever patients.

20 Aug 2015

Envarsus XR granted FDA orphan drug designation for prophylaxis of organ rejection in kidney transplant patients

Veloxis Pharmaceuticals A/S, today announced that Envarsus XR was granted Orphan Drug status by the U.S. Food and Drug Administration for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Envarsus XR received marketing authorization from the FDA on July 10, 2015.

14 Aug 2015

High-risk patients not receiving recommended treatment for blood clots

Venous thromboembolism (VTE), encompassing deep-vein thrombosis (DVT), or blood clots in leg veins, and pulmonary embolism (PE), or clots that travel to the lungs, is the most common cause of preventable death in hospital settings. While these clots can be prevented by an approach called VTE prophylaxis, and this reduces mortality by as much as 80%, VTE prophylaxis is not universally prescribed for high-risk patients.

10 Aug 2015

Imaging studies required to diagnose traumatic injuries in pregnant women can be safe when used properly

According to a new study in the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), imaging studies necessary to diagnose traumatic injuries sustained by pregnant women are safe when used properly.

7 Aug 2015

Pitt investigators to lead $5 million initiative to monitor resistance to HIV prevention drugs in sub-Saharan Africa

Infectious diseases researchers from the University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to monitor drug resistance during the rollout of HIV prevention drugs in sub-Saharan Africa.

4 Aug 2015

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million.

24 Jul 2015

Study: Cash to stay in school did not reduce HIV risk among young women in South Africa

A Phase III, individually randomized trial has found conditional cash transfers for school attendance did not reduce the risk of HIV among high-school aged women in South Africa, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada.

22 Jul 2015

Young, single South African women adhere well to daily PrEP regimen to prevent HIV infection

A clinical study funded by the National Institutes of Health has found that young, single black women in South Africa adhered to a daily pill regimen to prevent HIV infection--an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP. This finding is the first strong indication that this population at substantial HIV risk could accept and reliably adhere to daily PrEP dosing.

22 Jul 2015

Phase II open-label study demonstrates that high-risk populations adhere well to daily regimen of PrEP

Results from HPTN 067, a Phase II, randomized, open-label study, demonstrate most study participants had higher coverage of sex events and better adherence when they were assigned to the daily dosing arm, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada.

21 Jul 2015

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.

11 Jul 2015

Three South Florida research centers receive Campbell Foundation grants for HIV/AIDS studies

New research is taking place all around the world in the fight to find a cure for AIDS. But did you know that some critical research is taking place in our own backyard? That’s why The Campbell Foundation recently provided three South Florida research centers each with $30,000 fast-track grants to assist them with their ground-breaking investigations.

9 Jul 2015

SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, antiemetics expert and ESMO spokesperson Fausto Roila said, putting into perspective the results of a Japanese study presented today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.

2 Jul 2015

CSL Behring presents Phase I/III rVIII-SingleChain hemophilia A data at 2015 ISTH Congress

CSL Behring today presented data from a Phase I/III study on the efficacy and safety of its novel investigational recombinant factor VIII single chain in adolescents and adults with hemophilia A during a late breaking abstract session at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress.

25 Jun 2015